Key result
This review discusses the current experience with viscoelastic hemostatic assays for platelet function testing and monitoring antiplatelet therapy in atherosclerotic vascular diseases.
Why the study?
Viscoelastic hemostatic assays could theoretically overcome limitations of currently available platelet function testing assays for monitoring response to antiplatelet therapy in atherosclerotic cardiovascular diseases.
Viscoelastic hemostatic assays may offer an alternative to traditional platelet function testing for monitoring antiplatelet therapy in atherosclerotic cardiovascular diseases.
Current experience with viscoelastic assays for platelet monitoring remains exploratory; leaves open prospective validation before clinical use.
Platelets play crucial role in acute vascular atherosclerotic diseases, including myocardial infarction and stroke. Additionally, platelet aggregation is a key target of antiplatelet agents, forming the keystone of pharmacotherapy of various atherosclerotic cardiovascular diseases. Thromboelastography and thromboelastometry, representing currently available viscoelastic hemostatic assays (VHA), are designed as whole blood, real-time analyzers of clot formation and clot resolution. These assays could, in theory, overcome some limitations of currently available platelet function testing assays. This article reviews the current experience with the use of VHA for platelet function testing and for monitoring of the response to antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Samoš et al. (2021) conducted a review in Atherosclerotic vascular diseases. Viscoelastic hemostatic assays (VHA) was evaluated. This review discusses the current experience with viscoelastic hemostatic assays for platelet function testing and monitoring antiplatelet therapy in atherosclerotic vascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: